Catch up on a variety of FDA news in radiology from the past week.
|Articles|April 16, 1997
Sterling inks Direct Radiography deal
Sterling Diagnostic Imaging of Glasgow, DE, last week announced the signing of a seven-year, $10 million agreement to supply its Direct Radiography and PACS technology to a Canadian healthcare provider. The deal makes Atlantic Health Sciences (AHSC) of
Advertisement
Sterling Diagnostic Imaging of Glasgow, DE, last week announced the signing of a seven-year, $10 million agreement to supply its Direct Radiography and PACS technology to a Canadian healthcare provider. The deal makes Atlantic Health Sciences (AHSC) of Saint John, New Brunswick, one of the first commercial installations of Sterling's Direct Radiography technology.
Under the agreement, Sterling will supply a second-generation Linx network to six AHSC facilities spread over a 250-km area. The installation will include image management workstations supplied by Sterling partner ISG Technologies of Mississauga, Ontario.
Once the network is in place, Sterling will integrate its Direct Radiography selenium-based digital image capture system into the network when DR is commercially available in early 1998. Sterling officials say the installation is notable in that it will represent a model for how DR can be integrated into PACS networks.
Advertisement
Related to this article
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Catch up on the top radiology content of the past week.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
2
Diagnostic Imaging’s Weekly Scan: September 13 — September 19
3
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
4
Prostate MRI Study Links Lower ACD Values on DWI to Higher Long-Term Risk of Distant Metastases
5